Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET

Company Participants

Sherry Aulin - Chief Financial Officer

Ian Mortimer - President and Chief Executive Officer

Chris Kenney - Chief Medical Officer

Chris Von Seggern - Chief Commercial Officer

Conference Call Participants

Paul Matteis - Stifel

Andrew Tsai - Jefferies

Tessa Romero - JP Morgan

Brian Abrahams - RBC Capital Markets

Madhumita Yennawar - SVB Securities

Laura Chico - Wedbush

Yatin Suneja - Guggenheim

David Hoang - SMBC Nikko Securities

Lachlan Hanbury-Brown - William Blair

Operator

Good day, and thank you for standing by. Welcome to the Q3 2022 Xenon Pharmaceuticals, Inc. Earnings Conference Call. After the speakers presentation there will be a question and answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Sherry Aulin, Chief Financial Officer. Please go ahead.

Sherry Aulin

Thank you, and good afternoon, everyone. Thank you for joining us on our call and webcast to discuss Xenon's third quarter 2022 financial and operating results.

Joining me are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Dr. Chris Von Seggern, Xenon's Chief Commercial Officer. Ian and I will open today's call with -- sorry, Ian will open today's call with a summary of progress across our pipeline. Chris Kenney will provide additional detail around our recently launched XEN1101 Phase 3 program, and I will summarize this quarter's financial results, progress within our partnered programs and our anticipated company milestone events. Chris Von Seggern will be available during our Q&A session to address questions around our commercialization strategies.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding our and our collaborators' development plans, anticipated regulatory interactions and submissions anticipated results and related time lines; the potential efficacy, safety profile, addressable market and commercial potential of our proprietary and partnered product candidates; the efficacy of our trial designs and anticipated enrollment; the potential receipt of milestone payments and royalties from our collaborators; our expectation of having sufficient cash to fund operations into 2026 and the timing of potential release of future clinical data.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings.